Risk attribution — Kenyatta Lemke

v1.0 · cal 2026-05-22

Component breakdown showing every feature that contributed to this patient's risk score.

Computed ≠ stored(J vs I)Open patient detail

Computed score

100

Group J · Stage IV / progressing

Stored A–J score

Group I · On treatment

Score buildup

Baseline 5 + +163 positive = 100

BaselineDemographicSymptomComorbidityImagingProcedurePathologyTreatmentFollow-up

Demographic

Subtotal +5

Age ≥ 70
Advanced age is an independent risk factor for PDAC.
Evidence: Current age 75· Threshold: 70 years
+5

Symptom

Subtotal +27

Abdominal pain at age ≥ 50
Unexplained abdominal pain in a patient over 50 warrants pancreas evaluation.
Evidence: Onset 2024-09-29· Triggers PANDA group C
+14
Jaundice
Painless jaundice is a hallmark presentation of pancreatic head adenocarcinoma.
Evidence: Onset 2024-10-19
+13

Comorbidity

Subtotal +26

Has chronic condition(s)
Chronic disease burden warrants ongoing surveillance.
Evidence: 18 active conditions
+13
New-onset T2DM after age 50
New-onset diabetes after 50 has 6–8× elevated PDAC risk in the year following diagnosis.
Evidence: T2DM onset at age 73· Triggers PANDA group D
+13

Imaging

Subtotal +10

CT of abdomen on record
Imaging suggests the patient has been worked up for pancreatic concern.
Evidence: CT on 2025-03-28
+10

Procedure

Subtotal +42

EUS performed
EUS is the highest-resolution modality for sub-cm pancreatic lesions; performance implies clinical concern.
Evidence: Endoscopic ultrasonography of pancreas on 2025-01-07· Triggers PANDA group G
+20
Tissue diagnosis procedure
Biopsy or resection indicates definitive workup or treatment.
Evidence: EUS-guided fine needle aspiration of pancreas on 2025-01-10
+22

Pathology

Subtotal +25

Pancreatic tumor confirmed
Confirmed pancreatic malignancy is the defining factor for groups H–J.
Evidence: Malignant neoplasm of head of pancreas· Triggers PANDA group H
+25

Treatment

Subtotal +20

Active chemotherapy
Active cytotoxic therapy implies confirmed malignancy with treatment intent.
Evidence: Cisplatin 50 MG Injection, Cisplatin 50 MG Injection· Triggers PANDA group I
+20

Follow-up

Subtotal +8

Missed surveillance
No encounter in over a year increases the chance of unrecognized progression.
Evidence: Last encounter 3302 days ago
+8

The Risk Engine computed group (J) is derived purely from the feature contributions above. The stored A–J group (I) comes from the cascade classifier in scripts/classify-risk.ts. Divergence between the two indicates a classifier rule that the scoring weights haven't captured, or vice versa — useful for calibration.